Literature DB >> 15895790

Hearing loss as a late complication of radiotherapy in children with brain tumors.

Glenn B Williams1, Larry E Kun, Jerome W Thompson, Herbert J Gould, Rose Mary S Stocks.   

Abstract

Late postirradiation hearing loss has been well described in the adult population. Few reports exist on the pediatric population. We conducted a retrospective review of 157 consecutive children with brain tumors treated exclusively with irradiation at St Jude Children's Research Hospital. Twenty-six patients developed a hearing loss, 74 did not, and 57 were excluded because of incomplete records. We report a statistically significant 27.41% cumulative risk of a stringent 20-dB hearing loss in the voice frequency range by the fifth year after radiotherapy. The right side demonstrated a significant frequency effect, with a higher incidence of loss in the higher-frequency region. We found no difference in cumulative incidence of hearing shift between the low-, middle-, and high-frequency ranges for either ear. This risk should be anticipated and managed as part of the treatment plan for radiotherapy for the treatment of malignancies. Radiation-induced hearing loss is important to acknowledge so that techniques of hyperfractionation, total dose, ports, preservative infusion medical therapy, or prolonged medical intervention (such as anticoagulants) can be developed that might reduce this disabling problem of postirradiation sensorineural hearing loss in future patients.

Entities:  

Mesh:

Year:  2005        PMID: 15895790     DOI: 10.1177/000348940511400413

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  5 in total

1.  Association of Hearing Impairment With Neurocognition in Survivors of Childhood Cancer.

Authors:  Johnnie K Bass; Wei Liu; Pia Banerjee; Tara M Brinkman; Daniel A Mulrooney; Amar Gajjar; Alberto S Pappo; Thomas E Merchant; Gregory T Armstrong; Deokumar Srivastava; Leslie L Robison; Melissa M Hudson; Kevin R Krull
Journal:  JAMA Oncol       Date:  2020-09-01       Impact factor: 31.777

2.  Carboplatin and ototoxicity: hearing loss rates among survivors of childhood medulloblastoma.

Authors:  Lindy Musial-Bright; Rüdiger Fengler; Günter Henze; Pablo Hernáiz Driever
Journal:  Childs Nerv Syst       Date:  2010-10-08       Impact factor: 1.475

3.  Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.

Authors:  Maryam Fouladi; Murali Chintagumpala; David Ashley; Stewart Kellie; Sridharan Gururangan; Tim Hassall; Lindsey Gronewold; Clinton F Stewart; Dana Wallace; Alberto Broniscer; Gregory A Hale; Kimberly A Kasow; Thomas E Merchant; Brannon Morris; Matthew Krasin; Larry E Kun; James M Boyett; Amar Gajjar
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

4.  Hearing Loss in Patients Who Received Cranial Radiation Therapy for Childhood Cancer.

Authors:  Johnnie K Bass; Chia-Ho Hua; Jie Huang; Arzu Onar-Thomas; Kirsten K Ness; Skye Jones; Stephanie White; Shaum P Bhagat; Kay W Chang; Thomas E Merchant
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544

5.  Prospective longitudinal assessment of sensorineural hearing loss with hyperfractionated radiation therapy alone in patients with average-risk medulloblastoma.

Authors:  Tejpal Gupta; Sarthak Mohanty; Sadhana Kannan; Rakesh Jalali
Journal:  Neurooncol Pract       Date:  2014-08-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.